Home / Centerstage / 2000 / august / Week 2 /
Chiron Corp. announces its acquisition of PathoGenesis Corp. for $700 million. This deal will allow Chiron to expand its portfolio of biopharmaceutical products and improve its research-and-development efforts for new drug therapies for infectious diseases. Chiron, based in Emeryville, California, is already involved in blood-testing and produces drug treatments for cancer, multiple sclerosis, ulcers, and vaccines for infectious diseases. Seattle-based PathoGenesis is known for its drug Tobi, which is used to treat lung infections associated with cystic fibrosis.
Monday, 14 August, 2000